Evidence map›Paper›PMID 32699827›Full record

ArticleInnovation in aging2020

National Partnership to Improve Dementia Care in Nursing Homes Campaign: State and Facility Strategies, Impact, and Antipsychotic Reduction Outcomes.

Stephen Crystal, Olga F Jarrín, Marsha Rosenthal, Richard Hermida, Beth Angell

Open access · goldAbstract read
In one paragraph

Article in Innovation in aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. A Nursing Home Clinician Survey to Explain Gabapentinoid Increases.Journal of the American Medical Directors Association · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Staff Attitudes Related to Antipsychotic Prescribing in Assisted Living.Journal of the American Medical Directors Association · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stephen CrystalInstitute for Health, Health Care Policy, and Aging Research, Rutgers, The State University of New Jersey, New Brunswick.
Olga F JarrínInstitute for Health, Health Care Policy, and Aging Research, Rutgers, The State University of New Jersey, New Brunswick.
Marsha RosenthalInstitute for Health, Health Care Policy, and Aging Research, Rutgers, The State University of New Jersey, New Brunswick.
Richard HermidaInstitute for Health, Health Care Policy, and Aging Research, Rutgers, The State University of New Jersey, New Brunswick.
Beth AngellSchool of Social Work, Virginia Commonwealth University, Richmond.
Rutgers, The State University of New Jersey · USVirginia Commonwealth University · US

Funding

New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9M
Center for Education and Research on Mental Health TherapeuticsU19HS021112 · AHRQ · RUTGERS, THE STATE UNIV OF N.J. · PI CRYSTAL, STEPHEN · 2011 to 2015
$3.9M
SMINET: Applying Evidence to Improve Care and Outcomes in Severe Mental IllnessR18HS023258 · AHRQ · RUTGERS, THE STATE UNIV OF N.J. · PI CRYSTAL, STEPHEN · 2014 to 2017
$3.7M
Improving Medication Safety in Nursing Home Dementia CareR18HS023464 · AHRQ · RUTGERS, THE STATE UNIV OF N.J. · PI CRYSTAL, STEPHEN · 2014 to 2016
$1.3M
Comparative effectiveness of home care environments for diverse elders' outcomesR00HS022406 · AHRQ · RUTGERS THE STATE UNIV OF NJ NEWARK · PI JARRÍN MONTANER, OLGA F. · 2016 to 2018
$695k
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAntipsychotic medications have been widely used in nursing homes to manage behavioral and psychological symptoms of dementia, despite significantly increased mortality risk. Use grew rapidly during the 2000s, reaching 23.9% of residents by 2011. A national campaign for safer dementia care in U.S. nursing homes was launched in 2012, with public reporting of quality measures, increased regulatory scrutiny, and accompanying state and facility initiatives. By the second quarter of 2019, use had declined by 40.1% to 14.3%. We assessed the impact of state and facility initiatives during the Campaign aimed at encouraging more-judicious prescribing of antipsychotic medications. RESEARCH DESIGN AND

methodsOur mixed-methods strategy integrated administrative and clinical data analyses with state and facility case studies.

resultsResults suggest that substantial change in prescribing is achievable through sustained, data-informed quality improvement initiatives integrating educational and regulatory interventions, supported by public quality reporting. Adequate staffing, particularly of registered nurses, is key to support individualized management of symptoms through nonpharmacological strategies. Case study results suggest that state and facility initiatives during the campaign achieved considerable buy-in for the goal of more conservative prescribing, through a social process of normalization. Reporting and reduction of antipsychotic use was not followed by increases in sedative-hypnotic medication use. Rather, sedative-hypnotic use declined in tandem with antipsychotic reduction, suggesting that increased attention to prescribing patterns led to more cautious use of other risky psychotropic medications. DISCUSSION AND IMPLICATIONS: Quality improvement initiatives to change entrenched but problematic clinical practices face many barriers to success, including provider-level inertia; perceptions that alternatives are not available; and family and staff resistance. Nevertheless, systemic change is possible through concerted, collaborative efforts that touch prescribing practices at multiple points; integrate educational and regulatory influences; activate local and state champions for improvement; foster reputational influences through public reporting and benchmarking; and support a social process of normalization of preferred care processes as a best practice that is in the interest of patients.

Indexed as

Alzheimer’s disease and related dementiasAntipsychoticsChemical restraintsSedative-hypnotics

Identifiers

PMID32699827
PMCPMC7365953
OpenAlexW3033857632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.